Seegene Germany

Seegene to Present at the 33rd annual J.P. Morgan Healthcare Conference


Jan 05, 2015

Seegene to Present
at the 33rd annual
J.P. Morgan Healthcare Conference

?Gaithersburg, Maryland and SEOUL, Korea, January 5, 2014 ? Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced that it will present at the 33rd annual J.P. Morgan Healthcare Conference on? Wednesday, January 14, 2015 at 10:00 a.m. PST in the Victor’s Room (32nd Floor) at the Westin St. Francis Hotel in San Francisco.

Dr. Jong-Yoon Chun, Founder and CEO of Seegene, will present on the company’s growth strategy, breakthrough MuDT™qPCR technology, and recent corporate developments, including Seegene’s global ODM supply agreement with Beckman Coulter and other potential partnerships with global IVD players.
The annual J.P. Morgan Healthcare Conference is the largest healthcare investment symposium in the industry. The expected attendance includes more than 300 companies, both public and private, to deliver presentations to more than 3,000 investors.
About Seegene
Seegene is the world’s leading developer of multiplex molecular technologies and multiplexed clinical molecular diagnostics. Seegene’s innovative proprietary technologies, including DPO™, TOCE™, mTOCE™ and MuDT™, can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility.? Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene endlessly strives toward the new possibility of a world free of disease.
For more information, please visit or call +301-762-9066.